Late psychiatric and neurocognitive effects of Chimeric Antigen Receptor (CAR)-T cell therapy warrant further investigation

Within the last decade, as interest has renewed in finding innovative ways to harness the immune system to treat cancer, chimeric antigen receptor (CAR) T cell therapy has risen to the helm in treatment of relapsed/refractory non-Hodgkin lymphoma (NHL). Engineering a patient's own T cells to directly target CD19-expressing lymphoma/leukemia cells has resulted in unprecedented response rates in heavily pre-treated patients, and the responses have proven durable for most NHL patients who achieve an early complete remission [1 –5].
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research